A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

NCT00000746 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: rgp120/HIV-1 SF-2
BIOLOGICAL: Env 2-3
BIOLOGICAL: HIVAC-1e
BIOLOGICAL: gp160 Vaccine (MicroGeneSys)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)